Enorama Pharma AB's total assets for Q1 2026 were kr22.95M, an increase of 177.77% from the previous quarter. SE:ERMA total liabilities were kr59.58M for the fiscal quarter, a 87.89% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.